Breaking News: Revolutionary COVID-19 Variant Vaccine Gets Green Light – What You Need to Know

The Ministry of Food and Drug Safety approved ‘Comirnaty J&N Wonju (Bretovameran)’ applied by Korea Pfizer Pharmaceuticals Co., Ltd. on August 30. This vaccine is scheduled to be used for seasonal vaccinations in 2024-2025.

The Ministry of Food and Drug Safety (Minister Oh Yoo-kyung) stated that since the COVID-19 virus continues to mutate, vaccines targeting mutant strains are being developed. This approval states that the vaccine uses mRNA designed to express the JN.1 mutant antigen as its active ingredient.

The efficacy and effect of ‘Comirnaty J.N.Wonju (Bretovameran)’ is to prevent COVID-19 in those aged 12 years or older, and 0.3 mL is administered as a single intramuscular injection without dilution. If you have previously received a COVID-19 vaccine, you should receive it at least 3 months later.

The Ministry of Food and Drug Safety operated a dedicated review team to intensively review the safety, efficacy, and quality of ‘Comirnaty J.N. Wonju (Bretovameran)’, and decided on the final product approval after comprehensively reviewing the advice of external experts including infectious disease specialists.

The Ministry of Food and Drug Safety expects that the COVID-19 vaccine recently approved in Korea will help reduce the spread and severity of COVID-19, and even after approval, it will do its best to thoroughly check the quality of the vaccine through national distribution approval and strengthen the safety management system such as collecting adverse events so that the public can receive the vaccine with confidence.